

Policies Repository



Policy Title Sumatriptan and naproxen sodium (Treximet™)

Policy Number FS.CLIN.58

Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product line, group or contract. Some medications may be subject to precertification, age, gender or quantity edits. Individual member benefits must be verified.

This Pharmacy Policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety or FDA approval may have changed. If the Medical/Pharmacy Reviewer is aware of any new information on the subject of this document, please provide it promptly to the Medical/Pharmacy Policy Department. This information may include new FDA approved indications, withdrawals or other FDA alerts. This type of information is relevant not only when considering whether this Policy should be updated, but also when applying it to current requests for coverage.

Members are advised to use participating pharmacies in order to receive the highest level of benefits.

Policy **Sumatriptan and naproxen sodium (Treximet™)** is indicated for the acute treatment of migraine attacks with or without aura in adults.

The use of Sumatriptan and naproxen sodium (Treximet™) requires prior authorization (ie, clinical pharmacy and/or Medical Director review).

Policy Description **Sumatriptan and naproxen sodium (Treximet™)** is a combination of Sumatriptan which is a 5-HT₁ receptor agonist that mediates vasoconstriction of the human basilar artery and vasculature of human dura mater, which correlates with the relief of migraine headache, and Naproxen which is a nonsteroidal anti inflammatory drug that inhibits the synthesis of inflammatory mediators.

Policy Guideline Inclusion **Sumatriptan and naproxen sodium (Treximet™)** is approved when **all** of the following inclusion criteria are present:

- Documentation of a diagnosis of migraine
- Documentation of a trial and failure of concurrent therapy with Imitrex and Naproxen containing product
- Documentation that the individual is 12 years of age or older

Policy Guideline Exclusion **Sumatriptan and naproxen sodium (Treximet™)** is denied when **any** of the following exclusion criteria are present:

- No documentation of a diagnosis of migraine
- No documentation of a trial and failure of concurrent therapy with Imitrex and Naproxen containing product
- The individual is less than 12 years of age

Policy List of Applicable Drugs

Brand Name	Generic Name

Treximet	sumatriptan and naproxen sodium
----------	------------------------------------

Dosing and Administration

Refer to the specific manufacturer's prescribing information for administration and dosage details, contraindications, and Black Box warnings.

Policy References

Treximet™ (sumatriptan succinate and naproxen sodium). In: Facts and Comparisons [online through Facts and Comparisons Online]. Indy, IN: Walter Kluwer Health Inc. Accessed July 29, 2008.

Treximet™ (sumatriptan succinate and naproxen sodium). In: Drugdex [online through Micromedex Healthcare Series]. Greenwood Village, CO: Thomson Micromedex. Accessed July 29, 2008.

Treximet™ (sumatriptan succinate and naproxen sodium). Research Triangle Park, NC 27709: GlaxoSmithKline; July 2008.

Policy Link to Related Policies

Printed

03/02/2009 10:12:53

The Policy Bulletins on this web site were developed to assist AmeriHealth and its subsidiaries ("AmeriHealth") in administering the provisions of the respective benefit programs, and do not constitute a contract. If you are an AmeriHealth member, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. AmeriHealth does not provide health care services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of AmeriHealth. If you have a specific medical condition, please consult with your doctor. AmeriHealth reserves the right at any time to change or update its Policy Bulletins. ©2008 AmeriHealth, Inc. All Rights Reserved. Current Procedural Terminology ©2008 American Medical Association. All Rights Reserved.